DK1257276T3 - Antivirale azaindolderivater - Google Patents

Antivirale azaindolderivater

Info

Publication number
DK1257276T3
DK1257276T3 DK01904970T DK01904970T DK1257276T3 DK 1257276 T3 DK1257276 T3 DK 1257276T3 DK 01904970 T DK01904970 T DK 01904970T DK 01904970 T DK01904970 T DK 01904970T DK 1257276 T3 DK1257276 T3 DK 1257276T3
Authority
DK
Denmark
Prior art keywords
azaindole derivatives
antiviral azaindole
antiviral
derivatives
azaindole
Prior art date
Application number
DK01904970T
Other languages
Danish (da)
English (en)
Inventor
John A Bender
Tao Wang
Zhongxing Zhang
Nicholas A Meanwell
Owen B Wallace
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1257276(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1257276T3 publication Critical patent/DK1257276T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01904970T 2000-02-22 2001-01-19 Antivirale azaindolderivater DK1257276T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22

Publications (1)

Publication Number Publication Date
DK1257276T3 true DK1257276T3 (da) 2006-04-10

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01904970T DK1257276T3 (da) 2000-02-22 2001-01-19 Antivirale azaindolderivater

Country Status (32)

Country Link
US (1) US20020061892A1 (es)
EP (1) EP1257276B1 (es)
JP (1) JP3868814B2 (es)
KR (1) KR100496574B1 (es)
CN (1) CN1404392A (es)
AR (1) AR029469A1 (es)
AT (1) ATE314072T1 (es)
AU (2) AU3289501A (es)
BR (1) BRPI0108485B1 (es)
CA (1) CA2400700C (es)
CO (1) CO5271657A1 (es)
CY (1) CY1107460T1 (es)
DE (1) DE60116260T2 (es)
DK (1) DK1257276T3 (es)
EG (1) EG24669A (es)
ES (1) ES2254367T3 (es)
HK (1) HK1052132A1 (es)
HU (1) HU229992B1 (es)
IL (1) IL150734A0 (es)
MX (1) MXPA02008113A (es)
MY (1) MY128458A (es)
NO (1) NO323564B1 (es)
NZ (1) NZ520317A (es)
PE (1) PE20020786A1 (es)
PL (1) PL357434A1 (es)
PT (1) PT1257276E (es)
RU (1) RU2259372C2 (es)
TR (1) TR200201961T2 (es)
TW (1) TWI293629B (es)
UY (1) UY26593A1 (es)
WO (1) WO2001062255A1 (es)
ZA (1) ZA200206073B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0206636B8 (pt) * 2001-02-02 2021-05-25 Bristol Myers Squibb Co composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003072028A2 (en) * 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CN1953985B (zh) * 2004-03-15 2010-06-09 布里斯托尔-迈尔斯斯奎布公司 哌嗪和取代的哌啶抗病毒药物的前药
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
AR050158A1 (es) 2004-06-09 2006-10-04 Glaxo Group Ltd Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
JP2009514790A (ja) 2005-07-22 2009-04-09 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法
US7598380B2 (en) 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
KR20100020478A (ko) * 2007-06-18 2010-02-22 사노피-아벤티스 Ｐ2ｙ12 길항제로서의 피롤 유도체
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
EP2240482B1 (en) 2008-01-31 2013-07-17 Sanofi Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
PL2323633T3 (pl) * 2008-09-04 2012-08-31 Viiv Healthcare Uk No 4 Ltd Stabilna kompozycja farmaceutyczna dla zoptymalizowanego dostarczania inhibitora zaczepu HIV
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
ES2636312T3 (es) 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
CN109528749B (zh) * 2017-09-22 2023-04-28 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
EP4225742A4 (en) 2020-10-05 2024-11-06 Enliven Inc 5- 6-AZAINDOL COMPOUNDS FOR INHIBITING BCR-ABL TYROSINE KINASES
CN112430223B (zh) * 2020-11-24 2022-11-25 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用

Also Published As

Publication number Publication date
CA2400700C (en) 2010-10-26
ES2254367T3 (es) 2006-06-16
NZ520317A (en) 2004-05-28
RU2002125494A (ru) 2004-03-20
TR200201961T2 (tr) 2002-12-23
NO20023981D0 (no) 2002-08-21
JP2003523392A (ja) 2003-08-05
HK1052132A1 (en) 2003-09-05
RU2259372C2 (ru) 2005-08-27
DE60116260T2 (de) 2006-08-31
PT1257276E (pt) 2006-05-31
DE60116260D1 (de) 2006-02-02
MY128458A (en) 2007-02-28
CA2400700A1 (en) 2001-08-30
KR100496574B1 (ko) 2005-06-22
ATE314072T1 (de) 2006-01-15
BR0108485A (pt) 2003-04-22
HU229992B1 (en) 2015-04-28
ZA200206073B (en) 2003-10-30
EG24669A (en) 2010-04-11
UY26593A1 (es) 2001-09-28
KR20020073598A (ko) 2002-09-27
TWI293629B (es) 2008-02-21
EP1257276A4 (en) 2004-10-27
NO20023981L (no) 2002-10-17
AU3289501A (en) 2001-09-03
HUP0301508A2 (hu) 2003-09-29
NO323564B1 (no) 2007-06-11
US20020061892A1 (en) 2002-05-23
AU2001232895B2 (en) 2005-03-17
WO2001062255A1 (en) 2001-08-30
AR029469A1 (es) 2003-07-02
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
CY1107460T1 (el) 2012-12-19
EP1257276A1 (en) 2002-11-20
PL357434A1 (en) 2004-07-26
EP1257276B1 (en) 2005-12-28
CO5271657A1 (es) 2003-04-30
CN1404392A (zh) 2003-03-19
MXPA02008113A (es) 2003-01-28
PE20020786A1 (es) 2002-09-06
JP3868814B2 (ja) 2007-01-17
BRPI0108485B1 (pt) 2016-08-23

Similar Documents

Publication Publication Date Title
DK1257276T3 (da) Antivirale azaindolderivater
NO20010743D0 (no) Antivirale indoloksoacetyl-piperazin-derivater
DE60119492D1 (de) Purinderivate
DK1296996T3 (da) Purinderivater
DE60026861D1 (de) Purin-derivate
ATE238336T1 (de) Purin-derivate
EE200100681A (et) Puriinderivaadid
ATE372988T1 (de) Pyrimidin-derivate
EE200300273A (et) Asendatud imidasopüridiinid
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate